Terminated PHASE2 INTERVENTIONAL 1-arm NCT01600053

Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia

A Phase II Trial of Revlimid® as Consolidation Treatment of Residual Disease in Patients With Chronic Lymphocytic Leukemia (CLL)

Sponsor: Celgene Corporation

Conditions Chronic Lymphocytic Leukemia

Interventions Lenalidomide

Updated 6 times since 2017 Last updated: Oct 24, 2016 Started: Nov 30, 2011 Primary completion: May 31, 2014 Completion: May 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

interim analysis showed that the trial will not meet the interim endpoint.

Other terminated trials from Celgene Corporation

More terminations from Celgene Corporation

Other Chronic Lymphocytic Leukemia trials with similar outcome

Browse all Chronic Lymphocytic Leukemia trials

This PHASE2 trial investigates Chronic Lymphocytic Leukemia and is currently terminated or withdrawn. Celgene Corporation leads this study, which shows 6 recorded versions since 2011 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Nov 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Celgene Corporation
Thomas Kipps

Data source: University of California, San Diego

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• La Jolla, United States